



FINAL STUDY REPORT OF ANDEXANET ALFA FOR BLEEDING WITH FACTOR XA INHIBITORS

Truman Milling, Saskia Middeldorp*, Lizhen Xu, Andrew Demchuk, John Eikelboom, Peter Verhamme, Alexander Cohen, Jan Beyer-Westendorf, C. Michael Gibson, Jose Lopez-Sendon, Mark Crowther, Ashkan Shoamanesh, Michiel Coppens, Jeannot Schmidt, Pierre Albaladejo, Stuart Connolly, on behalf of the ANNEXA-4 Investigators*

**Denotes co-first authors*





Results – Anti-FXa Activity

Change from baseline to on-treatment nadir
(median percent change)


apixaban (n=172) 146.9 to 10.0 ng/mL
(-93.3%; 95% CI, -94.2, -92.5%)

rivaroxaban (n=132), 214.6 to 10.8 ng/mL
(-94.2%; 95% CI, -95.1, -93.3%)

edoxaban (n=28) 121.1 to 24.4 ng/mL
(-71.3%; 95% CI, -82.3, -65.2%)

enoxaparin (n=17) 0.48 to 0.11 IU/mL
(-75.4%; 95% CI, -79.2, -66.7%)

Left column is the median percent change; Right column is the time-course of anti-FXa activity from baseline through 12 hours post treatment.






Anti-FXa-Mortality Correlation*

- No linear correlation in all patients
- Dichotomous correlation in all patients at anti-FXa 30 ng/mL nadir is likely artifactual
- In ≤ 75 -year age subgroup, linear correlation and dichotomous correlation at anti-FXa 40 ng/mL nadir and below

Beeswarm Plot of Logarithmic Transform of Anti-FXa Level at Nadir Stratified by Age





From bottom to top, horizontal red dotted lines correspond to nadir equal to 20, 30, 40, 50, 60, and 70, respectively. The blue horizontal solid lines represent the medians of the log(nadir).

*Excludes enoxaparin for different units of measure.



Anti-FXa-Hemostatic Efficacy Correlation

(Change in anti-FXa activity)





Conclusions

- 1) Andexanet reduced anti-FXa activity
- 2) Andexanet was associated with 80% good or excellent hemostatic efficacy
- 3) There were no thrombotic events after restart of oral anticoagulation
- 4) There was a correlation between lower anti-FXa and lower mortality in the subgroup of patients ≤ 75 years of age
- 5) There was a correlation between lower anti-FXa and hemostatic efficacy in the subgroup of patients with ICH